The global Recurrent Atrial Fibrillation Market is expected to reach USD 25.93 Billion by 2027, according to a new report by Emergen Research. The increasing incidence of recurrent atrial fibrillation is majorly associated with recurrent paroxysmal atrial fibrillation patients, with the occurrence of a family history of AFib, high blood pressure, sleep apnea, overuse of stimulants, alcohol consumption, obesity, thyroid disorders, diabetes, lung disease, severe infections, and stress.

Take a Break and Get a sample of the report: https://www.emergenresearch.com/request-sample/71

Factors driving this market include augmenting incidence rate of recurrent atrial fibrillation, new product launches for effective treatment of recurrent events, and improved reimbursement scenarios for recurrent AFib treatment drugs along with technological advancements are expected to become the most common growth factors globally in the coming years. Moreover, healthcare experts from the University of Pennsylvania have estimated that patients admitted to intensive care units for COVID-19 treatment are more likely to suffer from arrhythmia and atrial fibrillation. This would be alarming for cardiac patients and would lead to increased sales of atrial fibrillation associated drugs.

Global Recurrent Atrial Fibrillation Market COVID-19 Analysis

The report offers an extensive analysis of the factors that are likely to influence the growth of the industry. The research study considers the COVID-19 pandemic a key growth influencing factor. The pandemic has negatively impacted the Recurrent Atrial Fibrillation industry through disruptions in global supply chains and grueling economic conditions. The report extensively analyzes the impact of the pandemic on the Recurrent Atrial Fibrillation market on a global as well as regional scale. To be updated, the report is furnished with the latest impact of the currently unfolding coronavirus pandemic on the Recurrent Atrial Fibrillation industry. The pandemic began in late 2019 and hit the world in early 2020, disrupting the normal lives and affecting every segment of the world. The report covers the impact of the pandemic on the Recurrent Atrial Fibrillation market and its key segment. The report also offers an initial and future assessment of the impact of the pandemic on the Recurrent Atrial Fibrillation market and offers revenue estimations in a post-COVID-19 scenario.

Revenue and cost profit analysis of major player dominating the Recurrent Atrial Fibrillation market

The report also takes into consideration the effect of the different restrictions imposed in different regions on the Recurrent Atrial Fibrillation industry and its key segments. It also offers a current and future impact analysis of the pandemic on the overall Recurrent Atrial Fibrillation market.

The device type product segment is estimated to reach USD 5.88 billion by the year 2027 at a CAGR of 14.0% during the forecast period.

Electrophysiology can estimate the electrical activity of the heart while the catheter ablation technique is used to treat arrhythmia of specific types. Electrophysiology is regarded as the most effective method for recurrent episodes of atrial fibrillation after drugs remain ineffective to the patient’s body.

Key participants contributing significant market shares in the industry growth includes Johnson & Johnson, Medtronic Plc, Abbott Laboratories, Microport Scientific Corporation, Atricure Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Siemens AG, Koninklijke Philips N.V., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and GlaxoSmithKline.

Any information regarding report, Visit Here: https://www.emergenresearch.com/purchase-enquiry/71

The segmentation of the market is done on the basis of product types, application spectrum, and the key regions of the Recurrent Atrial Fibrillation market. Along with this, the report also provides extensive coverage of the key companies and their strategic schemes to gain a substantial market position.

  • Product Outlook (Revenue, USD Billion; 2017-2027)
    • Device
    • Surgical Devices
      1. Maze Surgery
      2. Catheter Ablation
      3. Radiofrequency Catheter Ablation
        1. Conventional RF Ablation Catheters
        2. Irrigated-tip RF Ablation Catheters
      4. Cryoablation
      5. Microwave Based Catheter Ablation
      6. Laser Based Catheter Ablation
      7. Navigational Advanced Mapping Accessories
    • Non-Surgical Devices
      1. Electric Cardioversion
      2. EP Ablation Catheters
      3. EP Diagnostic Catheter
      4. Conventional Diagnostic Catheters
        1. Fixed Diagnostic Catheters
        2. Steerable Diagnostic Catheters
      5. Advanced Diagnostic Catheters
      6. Mapping and Recording Systems
      7. Cardiac Monitors or Loop Recorders
      8. Access Devices
      9. Left Atrial Appendage and Closure Devices
      10. Intracardiac Echocardiography (ICE) Systems
    • Drugs
      1. Dabigatran (Pradaxa)
      2. Rivaroxaban (Xarelto)
      3. Apixaban (Eliquis)
      4. Edoxaban (Savaysa)
      5. Warfarin (Coumadin)
      6. Others
    • Application Outlook (Revenue, USD Billion; 2017-2027)
      • EP Ablation
      • Diagnostic
      • Surgical Cardiac
    • End Users Outlook (Revenue, USD Billion; 2017-2027)
      • Hospitals
      • Cardiac Centers
      • Ambulatory Care Centers

The report offers a comprehensive overview of the global Recurrent Atrial Fibrillation market scenario pertaining to market value, volume, production and consumption rates, and market segmentation based on types, regions, and applications.

North America is the leading market segment, with a revenue of USD 4.04 billion in 2019 due to the high prevalence of recurrent atrial fibrillation in the U.S and Canada. North America holds the highest share of the recurrent atrial fibrillation market, with a CAGR of 13.1%. The incidence rate of surgical procedures in the U.S. is increasing gradually. Disease prevailing eating habits and dietary behaviors have led to a high incidence of Atrial Fibrillation in the region.

Regional Outlook (Revenue, USD Billion; 2017-2027)

  • North America
    1. S
    2. Canada
  • Europe
    1. Germany
    2. France
    3. UK
    4. Spain
    5. Italy
    6. Rest of the Europe
  • Asia Pacific
    1. China
    2. India
    3. Japan
    4. Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America
    1. Brazil

Request customization of the report: https://www.emergenresearch.com/request-for-customization/71

Key Questions Addressed in the Report:

  • Who are the leading players of the Recurrent Atrial Fibrillation industry?
  • Which region is expected to dominate the market in the coming years?
  • What are the key applications of the Recurrent Atrial Fibrillation market?
  • Which segment is expected to garner traction during the coming years?
  1. Report Overview

1.1 Research Scope

1.2 Key Recurrent Atrial Fibrillation market segments

1.3 Target players

1.4 Market analysis by type

1.5 Market analysis by application

1.6 Key learning objectives

1.7 Report timeline

  1. Global Growth Trends

2.1 Global Recurrent Atrial Fibrillation market size

2.2 Latest trends of the Recurrent Atrial Fibrillation market by region

2.3 Key corporate trends

About Us:

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: [email protected]

Facebook | LinkdIn | Twitter | Blogs

Leave a comment

Your email address will not be published. Required fields are marked *